<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lobe Sciences Ltd — News on 6ix</title>
<link>https://6ix.com/company/lobe-sciences-ltd</link>
<description>Latest news and press releases for Lobe Sciences Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 10:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lobe-sciences-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836837f78dffbe2df1694ed.webp</url>
<title>Lobe Sciences Ltd</title>
<link>https://6ix.com/company/lobe-sciences-ltd</link>
</image>
<item>
<title>Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-ltd-announces-closing-of-non-brokered-private-placement-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-ltd-announces-closing-of-non-brokered-private-placement-and-provides-corporate-update</guid>
<pubDate>Mon, 20 Apr 2026 10:00:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / April 20, 2026 /Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is pleased to announce ...</description>
</item>
<item>
<title>Lobe Sciences Ltd. Announces Non-Brokered Private Placement</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-ltd-announces-non-brokered-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-ltd-announces-non-brokered-private-placement</guid>
<pubDate>Sat, 11 Apr 2026 00:00:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / April 10, 2026 /Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is pleased to announce ...</description>
</item>
<item>
<title>Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-ltd-reports-improved-financial-position-and-strategic-update</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-ltd-reports-improved-financial-position-and-strategic-update</guid>
<pubDate>Wed, 25 Mar 2026 12:20:00 GMT</pubDate>
<description>Liabilities reduced 81%, from $2.35M to $0.44M Cash increased more than 24x, from $0.24M to $5.99M Net working capital improved by $6.1M, from ($2.01M) to $4.05M Outstanding warrants reduced by ~70%, from 43M to 13M VANCOUVER, BC / ACCESS Newswire ...</description>
</item>
<item>
<title>Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-announces-appointment-of-mr-mirza-rahimani-cpa-ca-as-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-announces-appointment-of-mr-mirza-rahimani-cpa-ca-as-chief-financial-officer</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / March 9, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, with principal executive offices in Florida. The Company ...</description>
</item>
<item>
<title>Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-ltd-announces-presence-in-miami-during-the-jefferies-and-leerink-healthcare-conferences-7</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-ltd-announces-presence-in-miami-during-the-jefferies-and-leerink-healthcare-conferences-7</guid>
<pubDate>Thu, 05 Mar 2026 12:40:00 GMT</pubDate>
<description>VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / March 5, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, with principal executive offices in ...</description>
</item>
<item>
<title>Lobe Sciences Reports First Quarter 2026 Results and Highlights</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-reports-first-quarter-120000595</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-reports-first-quarter-120000595</guid>
<pubDate>Tue, 03 Feb 2026 12:00:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / February 3, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported unaudited ...</description>
</item>
<item>
<title>Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-advances-governance-capital-120000743</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-advances-governance-capital-120000743</guid>
<pubDate>Tue, 13 Jan 2026 12:00:00 GMT</pubDate>
<description>VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 13, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing therapies for diseases with ...</description>
</item>
<item>
<title>Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-reports-fy2025-stronger-135500311</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-reports-fy2025-stronger-135500311</guid>
<pubDate>Thu, 08 Jan 2026 13:55:00 GMT</pubDate>
<description>Balance Sheet and Sharpened Strategy VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 8, 2026 /Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases ...</description>
</item>
<item>
<title>Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-reports-fiscal-2025-110000964</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-reports-fiscal-2025-110000964</guid>
<pubDate>Tue, 06 Jan 2026 11:00:00 GMT</pubDate>
<description>VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 /Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported ...</description>
</item>
<item>
<title>Lobe Sciences Completes Debt Settlement to Improve Balance Sheet</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-completes-debt-settlement-035000071</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-completes-debt-settlement-035000071</guid>
<pubDate>Fri, 24 Oct 2025 03:50:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / October 23, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops novel therapies through a scalable model of shared services, ...</description>
</item>
<item>
<title>Lobe Sciences Improves Balance Sheet</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-improves-balance-sheet-105000108</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-improves-balance-sheet-105000108</guid>
<pubDate>Thu, 09 Oct 2025 10:50:00 GMT</pubDate>
<description>VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / October 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops novel therapies through a scalable model of shared ...</description>
</item>
<item>
<title>Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-ltd-attend-arcstone-035000876</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-ltd-attend-arcstone-035000876</guid>
<pubDate>Tue, 16 Sep 2025 03:50:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - September 15, 2025) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming ArcStone-Kingswood Growth Summit in Toronto, taking place at the St. Regis Toronto on September 18, 2025. Dr. Frederick D Sancilio, CEO of Lobe...</description>
</item>
<item>
<title>Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-ltd-cynaptec-pharmaceuticals-035000891</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-ltd-cynaptec-pharmaceuticals-035000891</guid>
<pubDate>Wed, 10 Sep 2025 03:50:00 GMT</pubDate>
<description>VANCOUVER, B.C. / ACCESS Newswire / September 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet ...</description>
</item>
<item>
<title>Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-announces-appointment-marco-035000649</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-announces-appointment-marco-035000649</guid>
<pubDate>Tue, 09 Sep 2025 03:50:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / September 8, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant ...</description>
</item>
<item>
<title>Lobe Sciences Announces the Closing of the Previously Announced Private Placement</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-announces-closing-previously-030000625</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-announces-closing-previously-030000625</guid>
<pubDate>Fri, 15 Aug 2025 03:00:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 14, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical ...</description>
</item>
<item>
<title>Lobe Sciences Announces $341,425 CAD Private Placement for General Corporate Purposes</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-announces-341-425-041000706</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-announces-341-425-041000706</guid>
<pubDate>Tue, 29 Jul 2025 04:10:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), ...</description>
</item>
<item>
<title>Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-ltd-engages-arcstone-040800791</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-ltd-engages-arcstone-040800791</guid>
<pubDate>Tue, 29 Jul 2025 04:08:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases, today announced its formal engagement with ...</description>
</item>
<item>
<title>Lobe Sciences Ltd. Announces Debt Settlement</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-ltd-announces-debt-015500566</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-ltd-announces-debt-015500566</guid>
<pubDate>Thu, 17 Jul 2025 01:55:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / July 16, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company committed to developing innovative treatments for underserved diseases, today announced that it has settled an outstanding ...</description>
</item>
<item>
<title>Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-announces-validation-european-040100775</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-announces-validation-european-040100775</guid>
<pubDate>Tue, 08 Jul 2025 04:01:00 GMT</pubDate>
<description>European Unitary Patent EP4117446 Validated - Lobe Sciences secures patent protection in 17 EU member states for its DHA and egg yolk-based composition designed to manage Sickle Cell Disease. Covers Altemia(R) Medical Food Formula - The patented composition ...</description>
</item>
<item>
<title>Lobe Sciences Moves Forward with Development of Conjugated Psilocin(TM) Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals</title>
<link>https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-moves-forward-development-035800200</link>
<guid isPermaLink="true">https://6ix.com/company/lobe-sciences-ltd/news/lobe-sciences-moves-forward-development-035800200</guid>
<pubDate>Wed, 18 Jun 2025 03:58:00 GMT</pubDate>
<description>New subsidiary, Cynaptec Pharmaceuticals, established to hold global rights to Conjugated Psilocin™ $6 million investment in Cynaptec Pharmaceuticals secured to advance research and early-stage clinical trials for chronic cluster headaches and ...</description>
</item>
</channel>
</rss>